Placebo News and Research RSS Feed - Placebo News and Research

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

Adults with asthma who were treated with one-dose dexamethasone in the emergency department had only slightly higher relapse than patients who were treated with a 5-day course of prednisone. [More]
Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy. [More]
HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of inhaled corticosteroid (ICS) reduction among adults with HDM allergy-related asthma not well controlled by ICS, according to a study appearing in the April 26 issue of JAMA. [More]
Updated guidance on botulinum toxin formulations for four indications

Updated guidance on botulinum toxin formulations for four indications

The American Academy of Neurology has issued an update to its 2008 guidelines on the use of botulinum toxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache. [More]
Nutritional supplements can enhance effectiveness of antidepressants

Nutritional supplements can enhance effectiveness of antidepressants

An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression. [More]
Hydrocortisone drug can also prevent lung damage in premature babies

Hydrocortisone drug can also prevent lung damage in premature babies

Research from Ann & Robert H. Lurie Children's Hospital of Chicago conducted in mice shows the drug hydrocortisone -- a steroid commonly used to treat a variety of inflammatory and allergic conditions -- can also prevent lung damage that often develops in premature babies treated with oxygen. [More]
Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. [More]
FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer's disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies. [More]
Clinical study shows watercress extract inhibits carcinogen activation in cigarette smokers

Clinical study shows watercress extract inhibits carcinogen activation in cigarette smokers

Watercress extract taken multiple times a day significantly inhibits the activation of a tobacco-derived carcinogen in cigarette smokers, researchers at the University of Pittsburgh Cancer Institute, partner with UPMC Cancer Center, demonstrated in a phase II clinical trial presented today at the American Association for Cancer Research Annual Meeting in New Orleans. [More]
Two Ebola vaccine candidates show promise in clinical trial

Two Ebola vaccine candidates show promise in clinical trial

An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. [More]
New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

A clinical study evaluating a new hypothesis that an inexpensive drug with a simple treatment regimen can prevent type 1 diabetes will be launched in Dundee tomorrow. [More]
Psilocybin administration reduces reaction to social rejection in associated brain areas

Psilocybin administration reduces reaction to social rejection in associated brain areas

Social ties are vital for mental and physical health. However, psychiatric patients in particular frequently encounter social exclusion and rejection. Furthermore, psychiatric patients often react more strongly to social rejection than healthy persons and this can have negative consequences for the development and treatment of psychiatric disorders. [More]
AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research. [More]
Computer-based cognitive remediation at home can improve cognitive symptoms in MS patients

Computer-based cognitive remediation at home can improve cognitive symptoms in MS patients

Cognitive impairment is one of the core symptoms of multiple sclerosis (MS) -- and one of its most troubling concerns for many people with the condition. Now, a new study from NYU Langone Medical Center may provide hope for symptomatic relief for some of the cognitive issues associated with the neurological disease. [More]
Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

Innate Immunotherapeutics Limited has closed enrolment into the Company's Phase 2B placebo controlled efficacy trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). The study has exceeded the original recruitment target of 90 subjects with the successful enrolment this week of the 93rd patient. [More]
Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
PTSD patients carry long-term burden even with early clinical interventions

PTSD patients carry long-term burden even with early clinical interventions

The majority of people with post-traumatic stress disorder (PTSD) recover after early treatment -- but a substantial number still suffer for years after a traumatic event even with early clinical interventions, according to a study publishing online April 12, 2016 in The Journal of Clinical Psychiatry. [More]
RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). [More]
Zonisamide relieves myoclonus dystonia motor symptoms

Zonisamide relieves myoclonus dystonia motor symptoms

A randomised crossover trial shows that zonisamide significantly improves motor symptoms and related disability in adults with myoclonus dystonia. [More]
Innovative HIV vaccine candidate generates protection against repeated AIDS virus exposures

Innovative HIV vaccine candidate generates protection against repeated AIDS virus exposures

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study. [More]
Advertisement
Advertisement